Isotretinoin
Pronunciation: /ˌaɪsəʊˈtrɛtɪnɔɪn/
An oral retinoid used in the treatment of severe nodular acne, known for its teratogenicity and mandatory pregnancy prevention requirements.
Full Definition
Isotretinoin is a systemic 13-cis-retinoic acid derivative indicated for the treatment of severe, recalcitrant nodular acne unresponsive to conventional therapies. Its mechanisms include reduction of sebum production, normalisation of follicular keratinisation, and suppression of Propionibacterium acnes (now Cutibacterium acnes) colonisation. It carries a Black Box Warning (US) and pregnancy prevention program obligations (EU: Pregnancy Prevention Programme; UK: RoAccutane® Pregnancy Prevention Programme) owing to its potent teratogenicity. Editors working on patient information materials or prescribing documents must ensure all mandatory safety warnings, monitoring requirements, and female contraception guidance are present and correctly worded. The trade name 'Roaccutane' (UK/EU) or 'Accutane' (US) should not be substituted for the INN 'isotretinoin' in clinical and regulatory documents.
Usage
Usage note: Use the INN 'isotretinoin' in clinical/regulatory documents. Trade names (Roaccutane, Accutane) are appropriate only in patient-facing materials where brand clarity aids compliance. Ensure mandatory teratogenicity warnings are present in all patient-facing documents.
In Context
- "All female patients of childbearing potential must be enrolled in the Pregnancy Prevention Programme before isotretinoin is prescribed." — Prescribing information safety section
- "The editor replaced 'Roaccutane' with 'isotretinoin' throughout the clinical guideline, reserving the trade name only for the patient leaflet." — Medical writing editorial note